In vitro Characterization of a small molecule inhibitor of the alanine serine cysteine transporter -1 (SLC7A10) (pages 275–283)
Jeffrey M. Brown, Lisa Hunihan, Margaret M. Prack, David G. Harden, Joanne Bronson, Carolyn D. Dzierba, Robert G. Gentles, Adam Hendricson, Rudy Krause, John E. Macor and Ryan S. Westphal
Article first published online: 10 DEC 2013 | DOI: 10.1111/jnc.12618
Enhancing NMDA function by increasing synaptic D-serine is a proposed therapeutic approach for the treatment of schizophrenia. Synaptic D-serine levels are regulated by the alanine, serine, cysteine transporter 1 (asc-1). The following study describes the first novel asc-1 inhibitor, Compound 1 (BMS-466442), and provides a path forward for the development of additional asc-1 inhibitors.